Results 71 to 80 of about 1,228 (155)

Determination of Delafloxacin in Pharmaceutical Formulations Using a Green RP-HPTLC and NP-HPTLC Methods: A Comparative Study

Antibiotics, 2020
In this work; delafloxacin (DLFX) was determined using a validated green RP-HPTLC and NP-HPTLC methods in commercial tablets and in-house developed solid lipid nanoparticles (SLNs).
Prawez Alam, Essam Ezzeldin, Muzaffar Iqbal, Gamal A.E. Mostafa, Md. Khalid Anwer, Mohammed H. Alqarni, Ahmed I. Foudah, Faiyaz Shakeel   +7 more
doaj   +1 more source

Ciprofloxacin-Resistant Pseudomonas aeruginosa Lung Abscess Complicating COVID-19 Treated with the Novel Oral Fluoroquinolone Delafloxacin

Case Reports in Pulmonology, 2022
Purpose. We report the development of a lung abscess caused by a ciprofloxacin-resistant Pseudomonas aeruginosa in a patient with COVID-19 on long-term corticosteroid therapy.
Jürgen Panholzer, Matthias Neuboeck, Guangyu Shao, Sven Heldt, Markus Winkler, Paul Greiner, Norbert Fritsch, Bernd Lamprecht, Helmut Salzer   +8 more
doaj   +1 more source

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 2

, 2023
Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with
Thomas Guillard (12633958), Amelie Bosphore (14549900), Antoine Roux (14549894), Eric Farfour (11021923), Corentine Alauzet (14549885), Lise Cremet (14549888), Louise Ruffier d’Epenoux (14549879), Sophie Moussalih (14549891), Marc Vasse (335648), Sylvie C de Verdiere (14549897), Stephane Corvec (14549903), Anaelle Muggeo (14549882)   +11 more
core   +1 more source

Cefdinir reprograms Gram‐positive bacteria to synergize with lysozyme against superbugs

mLife, Volume 5, Issue 3, Page 355-368, June 2026.
Abstract Multidrug‐resistant (MDR) bacteria pose a critical global health threat, urgently requiring solutions. Cefdinir, the highest‐selling third‐generation cephalosporin but one now facing clinical obsolescence due to escalating resistance, is conventionally classified as a nascent cell wall synthesis inhibitor.
Qi Zhang, Yang Yang, Shuqi Li, Zhao Liu, Chun‐Kit Lee, Chi‐Bun Ko, Qian Zhao   +6 more
wiley   +1 more source

P41 Use of delafloxacin in osteomyelitis: a case report

JAC-Antimicrobial Resistance, 2023
Abstract Background Data and experience with delafloxacin use in osteomyelitis (OM) and other deep-seated infections are limited, yet the burden of OM on healthcare systems is significant. We hereby describe the first case, to our knowledge, of delafloxacin use in OM.
Vidwans, Madhuri, Mitria, Andra, Kandil, Hala   +2 more
openaire   +1 more source

Synthesis of an Enzyme‐Triggered Chitosan‐Based Drug Delivery System for Peri‐Implantitis Prevention

Chemistry – A European Journal, Volume 32, Issue 16, 25 April 2026.
ABSTRACT Dental implants have become a leading solution for tooth loss, yet bacterial infections remain a major complication. Antibacterial implant coatings are an important approach to reduce or prevent bacterial infections at the implant. Given the oral cavity's complex microbiome and the importance of some commensal bacteria, it is crucial to ...
Nelly Senze Nnane, Amit Gaikwad, Muhammad Imran Rahim, Andreas Winkel, Oliver Hergert, Till Beuerle, Meike Stiesch, Henning Menzel   +7 more
wiley   +1 more source

Frontiers in the Management of Orthopaedic Periprosthetic Joint Infection

Journal of Orthopaedic Research, Volume 44, Issue 2, February 2026.
ABSTRACT Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty (TJA), one of the most frequently performed surgical procedures worldwide. Management of acute PJI commonly involves debridement, antibiotics, and implant retention (DAIR), though failure rates remain high due to antibiotic‐tolerant biofilms. Chronic
Michael F. Shannon, Victoria R. Wong, Samuelson E. Osifo, Timothy Edwards, Himanshu Rao, Jewelia Rempuszewski, Andrew J. Frear, Shaan Sadhwani, Neel B. Shah, Kenneth L. Urish   +9 more
wiley   +1 more source

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections [PDF]

Drugs, 2020
The global spread of antibacterial-resistant strains, especially methicillin-resistant Staphylococcus aureus (MRSA) for acute bacterial skin and skin structure infections (ABSSSIs), has driven the need for novel antibacterials. Delafloxacin [Quofenix™ (EU); Baxdela® (USA)], a new fluoroquinolone (FQ), has a unique chemical structure that enhances its ...
openaire   +2 more sources

Clinically Approved Antibiotics from 2010 to 2022

CHIMIA, 2023
This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives ...
Erik Jung, Karl Gademann
doaj   +1 more source

A New Class of Benzo[b]Thiophene‐1,3,4‐Oxadizole Bearing 1,2,4‐Oxadiazoles as Potent Antimicrobial Targets: Synthesis, Biological Evaluation, Docking, DFT and ADMET Studies

ChemistrySelect, Volume 11, Issue 3, 22 January 2026.
Benzo[b]thiophene‐1,3,4‐oxadizole and 1,2,4‐oxadiazole hybrids 9a–9l were tested against both antibacterial and anticancer, revealing interesting structure‐activity relationships. density functional theory calculations (DFTs) at the B3LYP/6–311++G (d,p).
Ravikumar Gupta Miriyala, Janardan Sannapaneni, Phani Raja Kanuparthy, Venkata Ramana Singamaneni, Tejeswara Rao Allaka, Pilli Veera Venkata Nanda Kishore   +5 more
wiley   +1 more source